Start-Up Spotlight: Cerebrotech Hopes To Launch Portable Stroke Test Device In 2018
Executive Summary
Results of the VITAL trial show Cerebrotech's non-invasive portable VIPS technology can distinguish patients with large-vessel occlusion strokes and large hemorrhagic strokes versus less-urgent strokes. The company hopes emergency responders will use its unique diagnostic visor to shorten the time it takes for patients suffering major strokes to get to a hospital that has the facilities to treat the stroke effectively.
You may also be interested in...
Medtronic’s Solitaire Gets STRATIS Real-World Stroke Boost
Registry data presented at the International Stroke Conference confirm that mechanical thrombectomy with Medtronic’s Solitaire stent retriever can be safely performed in community hospitals as effectively as it was in the randomized trials observed in randomized trials. The results also show that the benefits of transferring a patient with an acute ischemic stroke to a comprehensive stroke center are usually not worth the extra time it takes to transport the patient there.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.